M&A / Property
MMA.INC (NYSE American: MMA) Enters Exclusive 50/50 Revenue Share Peptide Partnership with Precision Peptide (CSE: BPC)
Precision Peptide Taps MMA’s 5 Million Combat Sports Fans to Muscle Into $300 Billion Wellness Market
Executive Summary
- On May 12, 2026, The Precision Peptide Company (BPC) announced an exclusive strategic marketing partnership with Mixed Martial Arts Group Limited (MMA.INC).
- MMA.INC operates a global combat sports digital ecosystem – including TrainAlta, BJJLink, MixedMartialArts.com – with 5 million social media followers, 530,000 user profiles, 75,000 active students, and 800 verified gyms.
- BPC will market and sell its U.S.-manufactured, FDA‑compliant peptide recovery and wellness products to MMA’s audience.
- Revenue‑sharing structure: first 12 months split 50/50 (BPC/MMA), then 75/25 in BPC’s favor from month 13 onward.
- Either party can terminate with 30 days’ written notice; a 12‑month “tail” continues MMA’s profit share on referred customers after termination.
- The agreement creates a capital‑light new vertical for MMA and opens a massive consumer channel for BPC without upfront cash investment.
Material Impact
- The partnership represents a genuinely new and unexpected commercial avenue for BPC, tapping into a large, engaged, and combat‑sports‑focused audience that naturally overlaps with the peptide recovery market.
- It moves BPC significantly closer to real sales traction at scale, addressing the main uncertainty for a pre‑revenue stage company.
- The revenue‑sharing terms are favorable over time (75/25 after year one) and include a tail that incentivizes performance.
- Termination rights are broad (30‑day notice), but BPC has the ability to retain relationships built during the term.
- The news is material – it alters the growth trajectory from a product‑development story to a commercialization story with potential for near‑term revenues.
- The release was accompanied by a separate sector‑update release that highlighted industry tailwinds (Pfizer, Lilly, Hims & Hers, Amazon Pharmacy), further validating the market opportunity.
- This is not a Game Changer in the sense of a takeover or a first‑time investment by a legendary resource financier, but for a small‑cap company it is a strong positive catalyst.
BPC · Price
Company Overview
- The Precision Peptide Company Inc. is a biotechnology company focused on the development and commercialization of peptide‑based wellness and recovery products.
- Flagship project: BPC‑157 transdermal patch – a needle‑free, sustained‑release peptide delivery system designed to remove the injection barrier and bring peptides to the mainstream consumer market.
- Pipeline: A second product, the Immune Defense Patch (Thymosin Alpha‑1), is under development on the same delivery platform.
- Current revenue: The company generates some sales through its Amino Innovations oral peptide line, distributed across North America, but remains pre‑profit and pre‑significant revenue.
- Manufacturing: All products are manufactured in U.S. facilities that comply with FDA standards and undergo third‑party testing.
- Research collaboration: The company works with the Drug Development and Innovation Centre at the University of Alberta (Dr. Neal Davies, Dr. Raimar Loebenberg) on absorption and stability testing for the transdermal platform.
More from The Precision Peptide Company Inc.
Jun 23, 2026 · 07:31